{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=10&q=fallopian+tube",
    "query": {
      "q": "fallopian tube",
      "condition": "Ovarian Cancer",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 739,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=11&q=fallopian+tube&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Cancer&page=9&q=fallopian+tube&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T02:21:04.911Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01952249",
      "title": "A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Demcizumab",
          "type": "DRUG"
        },
        {
          "name": "Taxol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoMed Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "21 Years to 90 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2013-08-05",
      "completion_date": "2016-07-12",
      "has_results": false,
      "last_update_posted_date": "2020-09-09",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 3,
      "location_summary": "Oklahoma City, Oklahoma • Philadelphia, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01952249"
    },
    {
      "nct_id": "NCT03393884",
      "title": "Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "IMNN-001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Imunon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 130,
      "start_date": "2018-09-05",
      "completion_date": "2026-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Newport Beach, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03393884"
    },
    {
      "nct_id": "NCT05194072",
      "title": "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Peritoneal Neoplasms",
        "Fallopian Tube Neoplasms",
        "Triple Negative Breast Neoplasms",
        "HER2 Negative Breast Neoplasms",
        "Hormone Receptor Positive Breast Neoplasms",
        "Endometrial Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Cholangiocarcinoma",
        "Gallbladder Carcinoma",
        "Adenoid Cystic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Felmetatug Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2022-01-12",
      "completion_date": "2025-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 22,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194072"
    },
    {
      "nct_id": "NCT03412630",
      "title": "Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Computed Tomography Perfusion Imaging",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1,
      "start_date": "2018-12-13",
      "completion_date": "2020-07-22",
      "has_results": true,
      "last_update_posted_date": "2023-11-24",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03412630"
    },
    {
      "nct_id": "NCT05001282",
      "title": "A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Ovarian Carcinoma",
        "Endometrial Cancer",
        "Ovary Cancer",
        "Ovary Neoplasm",
        "Ovary Disease",
        "Ovary Metastasis",
        "Ovarian Diseases",
        "Ovarian Cancer Stage",
        "Ovarian Epithelial Cancer",
        "Ovarian Adenocarcinoma",
        "Ovarian Serous Adenocarcinoma",
        "Ovarian Neoplasm Epithelial",
        "Ovarian Cancer Recurrent",
        "Endometrial Diseases",
        "Endometrial Adenocarcinoma",
        "Endometrial Carcinosarcoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrioid Adenocarcinoma",
        "Endometrial Neoplasms",
        "Endometrial Cancer Recurrent",
        "Endometrioid Tumor",
        "Fallopian Tube Cancer",
        "Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "ELU001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Elucida Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2021-09-13",
      "completion_date": "2024-06-07",
      "has_results": false,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Margate",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001282"
    },
    {
      "nct_id": "NCT00287482",
      "title": "Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Essiac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Women and Infants Hospital of Rhode Island",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2005-10",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2007-02-12",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00287482"
    },
    {
      "nct_id": "NCT03321188",
      "title": "Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Epithelial Ovarian Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "HIPEC",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Andrea Jewell",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2017-12-15",
      "completion_date": "2024-12-15",
      "has_results": false,
      "last_update_posted_date": "2023-02-06",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03321188"
    },
    {
      "nct_id": "NCT00381888",
      "title": "Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer",
        "Endometrial Cancer",
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Thromboembolism",
        "Vaginal Cancer",
        "Vulvar Cancer"
      ],
      "interventions": [
        {
          "name": "fondaparinux sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 44,
      "start_date": "2007-01",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Upland, Pennsylvania",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Upland",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00381888"
    },
    {
      "nct_id": "NCT00466960",
      "title": "Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brenner Tumor",
        "Fallopian Tube Cancer",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mixed Epithelial Carcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Ovarian Undifferentiated Adenocarcinoma",
        "Peritoneal Cavity Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Stage III Ovarian Epithelial Cancer",
        "Stage IV Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "paclitaxel albumin-stabilized nanoparticle formulation",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2006-05",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-08-28",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00466960"
    },
    {
      "nct_id": "NCT02900560",
      "title": "Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "CC-486",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Translational Research in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 34,
      "start_date": "2016-12-20",
      "completion_date": "2021-05-27",
      "has_results": true,
      "last_update_posted_date": "2022-06-10",
      "last_synced_at": "2026-10-14T02:21:04.911Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900560"
    }
  ]
}